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Abstract
Background: Frequent rehospitalisations and poorer survival chances in heart failure (HF) patients may partly be
explained by poor medication adherence. There are multiple medication-related reasons for suboptimal adherence,
but psychological reasons may also be important. A novel TELEmonitoring device may improve MEDication
adherence in HF patients (TELEMED-HF). TELEMED-HF is a randomized, controlled clinical intervention trial designed
to examine (1) the efficacy and cost-efficiency of an electronic medication adherence support system in improving
and monitoring HF patients’ medication adherence; (2) the effect of medication adherence on hospitalizations and
health care consumption; as well as on (3) clinical characteristics, and Quality of Life (QoL); and (4) clinical,
sociodemographic, and psychological determinants of medication adherence.
Methods/Design: Consecutive patients with chronic, systolic HF presenting to the outpatient clinic of the
TweeSteden Hospital, The Netherlands, will be approached for study participation and randomly assigned (1:1)
following blocked randomization procedures to the intervention (n = 200) or usual care arm (n = 200). Patients in
the intervention arm use the medication support device for six months in addition to usual care. Post-intervention,
patients return to usual care only and all patients participate in four follow-up occasions over 12 months. Primary
endpoints comprise objective and subjective medication adherence, healthcare consumption, number of
hospitalizations, and cost-effectiveness. Secondary endpoints include disease severity, physical functioning, and
QoL.
Discussion: The TELEMED-HF study will provide us a comprehensive understanding of medication adherence in
HF patients, and will show whether telemonitoring is effective and cost-efficient in improving adherence and
preventing hospitalization in HF patients.
Trial registration number: NCT01347528.
Keywords: chronic heart failure, medication adherence, telemedicine, telemonitoring, intervention trial, determi-
nants of adherence
Background
The prevalence of symptomatic heart failure (HF) is
rapidly growing due to the aging of the population, suc-
cessful treatment of myocardial infarction, and increased
survival after an acute cardi a ce v e n t[ 1 , 2 ] .T h em o r e
frequent need for rehospitalisations and poorer survival
chances in the chronic HF population are associated
with major healthcare costs. For instance, almost 390
million Euros were spent on HF care in the Netherlands
in 2005, and it is expected that these costs increase dur-
ing the following decades [3].
Pharmacological treatment of HF typically consists of
a combination of ≥4 different types of medication [4]. A
major problem in HF management is poor medication
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adherence to treatment may to a great extent explain
frequent readmissions in HF patients [5], and is asso-
ciated with increased morbidity and mortality [6]. A
recent longitudinal study showed that medication adher-
ence rates above 88% were associated with a reduced
number of rehospitalisations and mortality rates com-
pared to non-adherent patients [7]. In this study, objec-
tive medication adherence was measured using an
electronic chip in the medication cap (“Medication
Event Monitoring”) that records each moment the cap is
removed from the medication bottle [7]. Hence, improv-
ing medication adherence may enhance cardiac prog-
nosis, reduce the number of HF-related hospital
readmissions, improve quality of life (QoL), increase sur-
vival, and reduce healthcare costs [8].
A novel tool to improve patient adherence is home tel-
emonitoring, permitting remote patient monitoring,
either by structured telephone support [9], or using tele-
care devices in conjunction with a telecommunication
system that electronically transfers patient data [10]. Two
meta-analyses have shown promising results concerning
the effect of telemonitoring on improving clinical out-
comes in HF patients, i.e. reducing cardiac-related hospi-
tal re-admissions and all-cau s em o r t a l i t yb yn e a r l yo n e
fifth, and reducing healthcare costs while improving QoL
[11,12]. Only one small study tried to improve medica-
t i o na d h e r e n c eu s i n gas p e c i f i ca d h e r e n c ed e v i c e( i . e .a
medication box transferring data to an electronic record),
and found that this device improved patients’ compliance
[10]. Most studies examining the efficacy of home tele-
monitoring in HF patients were either based on small
samples, were time-consuming due to extensive tele-
phone support, or did not investigate the effect of tele-
monitoring on longer term outcomes, or the clinical
course of HF [12]. A few major randomized controlled
clinical trials did use a prospective design [13,14], such as
TIM-HF with a long-term follow-up of 21 months [13].
However, these trials primarily focused on improving
clinical outcomes instead of improving medication adher-
ent behavior in HF patients.
When trying to improve patients’ adherence, it is
important to examine potential adherence modifiers
from a multidimensional perspective. Disease character-
istics, regimen related factors (e.g. polypharmacy), and
medication side-effects may cause people not to take
their medication [15,16]. Psychosocial and socio-eco-
nomic factors, such as social support, and patient-
related factors, such as self-care behavior, motivation,
beliefs in medication, mood, cognitive dysfunction, and
personality may also affect medication adherence in HF
patients [16]. Previous studies on clinical and psychoso-
cial factors that may affect medication adherence in HF
failed to find determinants of adherence [17,18].
However, these were all drug trials in which adherence
was around 90%, which is not representative of the HF
population in general, in which adherence rates are evi-
dently lower.
In summary, evidence suggests that medication adher-
ence in chronic HF patients is poor, and that it remains
unclear which method(s) may be effective in improving
medication adherence, ultimately improving the patient’s
prognosis and QoL. While some studies aimed to
improve medication adherence in HF patients, the
majority of the devices only recorded adherence, such as
“Medication Event Monitoring” [7]. In the present study,
the effectiveness of a novel Medication Adherence Sup-
port System (MASS) to improve medication adherence
will be investigated. The MASS supplies all pills put
together in one or two small bags at specified times
using pharmacy-prepared medication rolls. This makes
t h ei n t e r v e n t i o ne s p e c i a l l ys u i t a b l ef o rc h r o n i cH F
patients, who are mostly elderly, care dependent, and
o f t e nr e c e i v em u l t i p l ed i f f e r e n tt y p e so fm e d i c a t i o n .
MASS not only records adherence, but is also designed
to train medication adherent behavior, and is therefore a
behavior-based intervention.
Study objectives
The primary study objectives are to (ia)t e s tt h ee f f i c a c y
and cost-efficiency of the MASS (in addition to usual
care) in improving adherence as compared to usual care
alone (i.e. three visits to the HF nurse); and to (ib) inves-
tigate the effect of medication adherence on hospitaliza-
tions and health care consumption in HF patients.
The secondary objectives are to (iia) determine the
effect of medication adherence on clinical characteristics
(i.e., measures of disease severity, physical functioning,
cognitive function), and QoL; and to (iib) identify clini-
cal, sociodemographic, and psychological determinants
of subjective and objective medication adherence, while
examining their role in modulating adherence and the
effect of the MASS.
Study design
The TELEMED-HF study is a Dutch, open, prospective,
randomized, controlled clinical intervention trial (RCT)
designed to improve medication adherence using a tele-
monitoring solution in a large group of HF patients. Pri-
mary and secondary outcomes will be evaluated pre-
and post-intervention with a follow-up of 12 months.
The trial has been registered at http://www.Clinical-
Trials.gov (NCT01347528). TELEMED-HF is expected
to report its first results in autumn 2013.
Study population and eligibility criteria
Consecutive patients with a diagnosis of chronic, systolic
HF presenting to the HF outpatient clinic of the
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lands, will be approached for study participation and
randomized to the intervention arm (n = 200) or usual
care arm (n = 200) at inclusion. Eligible patients must
(a) have a diagnosis of stable HF, (b) New York Heart
Association (NYHA) functional class II-III, with a
decreased pump function (left ventricular ejection frac-
tion (LVEF) < 40%), (c) titrated to the most optimal
doses of ACE-inhibitor or angiotensin receptor blocker
(ARB), and beta-blocker, (d) receiving stable doses of at
least three HF medications for one month with no plans
to add or adjust HF medications or titrate further in the
immediate future, and (e) providing written informed
consent.
Exclusion criteria are: (a) age < 50 years, (b) diastolic
HF (intact pump function), (c) either myocardial infarc-
tion, or invasive treatment (percutaneous coronary inter-
vention (PCI) or coronary artery bypass grafting
(CABG)), or hospitalization within one month prior to
inclusion, (d) participation in another clinical trial, (e)
life-threatening co-morbid conditions (e.g., cancer), (f)
diminished mental capacities (suspected serious cogni-
tive decline will be confirmed by a Mini Mental State
Examination (MMSE score ≤24 [19])), (g) a history of
psychiatric disorders apart from affective disorders
(depression and anxiety disorders), (h) significant sight
and/or hearing impairment, and (i) insufficient knowl-
edge of the Dutch language.
Study procedures, randomization, and follow-up
The study protocol has been approved by the medical
ethics committee of the TweeSteden Hospital as well as
by the local regulatory authority of the TweeSteden
Hospital. The trial conforms to the principles most
recently outlined in the Declaration of Helsinki (2008).
All patients will be informed orally and in writing about
the purpose, rights, and possible benefits/risks of the
study prior to participation. We have guaranteed full
participation of the HF outpatient clinic of the TweeSte-
den hospital. Eligible patients will be invited to partici-
pate in the study during a regular visit to the HF nurse
or cardiologist at the HF outpatient clinic. After 4 to 7
days patients will be contacted by telephone and asked
for participation. Positively responding patients will then
sign the informed consent forms and receive an
appointment at the HF outpatient clinic within two
weeks for their baseline visit (T0).
Patients will be randomly assigned following a blocked
randomization procedure (computerized random num-
bers) to either the intervention arm or to usual care
(1:1). Due to the restriction of a limited number of
MASS devices at our disposal, the randomization proce-
dure will be performed per week so that each week a
maximum of 6 patients is assigned to either condition
arms. In order to prevent selection bias, the allocation
sequence will be concealed from the researcher and the
HF nurse enrolling and assessing patients in sequentially
numbered, opaque, and sealed envelopes. A second
researcher working outside the hospital will develop and
monitor the concealment system.
All patients will visit their HF nurse for their first
usual care visit (T0). Corresponding envelopes based on
t h eo r d e ro fi n c l u s i o ns e q u e n c ew i l lb eo p e n e do n l y
after completion of all baseline assessments during this
visit to allocate the intervention. If the patient has been
randomized to the intervention group, he/she will
receive the MASS device and instructions, and will be
fully explained how to use it. The intervention period
starts within two weeks after this visit, for a period of 6
months (see below for specific details on intervention).
All patients will return to the HF outpatient clinic
with a three-monthly frequency, meaning that in total
three usual care visits are included in the intervention
period. After the intervention period, all patients will
continue to receive usual care, and will participate in
four follow-up occasions at 9 (T2), 12 (T3), 15 (T4), and
18 months (T5) post-baseline that coincide with the reg-
ular three-monthly clinic appointments.
Every six months (i.e. at baseline (T0), at the end of
the intervention (T1), and at 6 (T3) and 12 (T5) months
thereafter), the following activities will take place in
both study conditions: (i) a blood draw assessment of
biochemical variables; (ii) a six-minute walk test; (iii) a
NYHA functional class determination following standar-
dized protocol; and (iv) an echocardiography to deter-
mine LVEF (%). The follow-up at 3 and 9 months will
consist of a telephone call, only requesting information
on healthcare consumption and adherence. The timeline
of the study design is demonstrated in Figure 1.
Over the 18-month study period as well as the year
before inclusion, retrospective refill rates will be
requested from the patients’ pharmacies. The general
practitioner of the patients will be informed of the
patients’ participation in the study and will be asked to
report the total number of patient visits to their clinic
by filling out a patient contact form sent by us every 6
months.
Study endpoints
The main study parameters include objective and sub-
jective medication adherence, number of hospitaliza-
tions, healthcare consumption and costs (see Table 1).
Objective medication adherence will be assessed using
the monitor output collected in a web-based application
(CarebyWeb), and the prescription refill records pro-
vided by the patients’ pharmacies. A cost-benefit analy-
sis will be assessed by means of the TiC-P questionnaire
[20] and event rate (and related DBC (diagnosis
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costs to treatments of specific patient groups)). The
TiC-P questionnaire will enable us to compare health-
care consumption in the intervention and control group.
The main secondary study parameters include QoL,
disease severity (NYHA functional class determination
following standardized protocol; LVEF using echocardio-
graphy), and exercise capacity (six-minute walk test; see
also Table 1). Other secondary variables are designed to
determine whether randomization was successful, to
assess their potentially moderating influence on adher-
ence, and to generate risk profiles of patients who may
or may not benefit from the intervention (see Table 1).
These include: (1) psychological and sociodemographic
variables; i.e. Type D personal i t y ,d e p r e s s i o n ,a n x i e t y ,
socio-economic status, age, gender, beliefs in medica-
tion, self-care behavior, and cognitive function; and (2)
clinical variables; i.e., self-reported medication side
effects; time since HF diagnosis; HF etiology; previous
cardiac events (MI), previous cardiac procedures (PCI,
CABG), previous cardiac devices (ICD, pacemaker),
number of hospitalizations for HF; blood pressure; cho-
lesterol; triglycerides; diabetes; atrial fibrillation; comor-
bidities; cardiac medication, other medication (including
Months 
usual care 
T0 
Randomization to 
intervention or 
usual care 
intervention 
0  6  9  12  15  18 
T1  T2  T3  T4  T5 
Figure 1 Timeline study procedure. The figure shows a timeline of the study procedure.
Table 1 Measures & design
Construct/
Measure
Methods of assessment T0
Pre
T1
Post
T2 T3 T4 T5
Primary outcomes
Adherence Objective: Monitor output X X
Refill rate pharmacy MR MR MR MR
Subjective: MAS, MOS-adhere Q Q T Q T Q
Healthcare
Consumption
Number of rehospitalisations, time to first HF-related hospitalization, visits to the GP and ER
due to cardiac causes, DBC codes
MR MR MR MR MR MR
TiC-P, Q Q TQ TQ
Secondary
outcomes
Physical function, 6-minute walk test A A A A
disease
progression
NYHA, LVEF SS S S
Quality of life KCCQ QQ Q Q
Predictors
Sociodemographic Self-report, postal code area Q
Self-care behavior EHFScBS-9 QQ Q Q
Cognitive function MMSE AA A A
Depression PHQ9, BDI10 QQ Q Q
Anxiety GAD7, SAD4 QQ Q Q
Type D
personality
DS14 QQ
NB. Multiple instruments are used to assess anxiety and depression since there is no gold standard or consensus which instruments to use in patients with
somatic disease. All psychological questionnaires are standardized and validated. Variables obtained from: S = standard measures in routine clinical care visits, A
= additional assessment physical/cognitive functioning, MR = medical records, Q = questionnaire, X = intervention, T = telephone call.
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BNP; parameters measured in standard clinical practice
(including liver function (ACAT, ALAT, Gamma GT),
hemoglobin, hematocrit, leukocytes, and kidney function
(urea and creatinine).
All endpoints will be assessed with standardized and
validated measures shown to have good psychometric
properties, usual care laboratory tests, physical examina-
tions, and pharmacy refill records (Table 1).
Event adjudication
An independent, blinded, clinical endpoint committee
will classify the number of all-cause and cardiac-related
deaths.
Intervention
Patients in the intervention group will be instructed to
use an electronic medication adherence monitor, the
MASS device, for a 6-month period and to visit the HF
outpatient clinic of the TweeSteden hospital 3 times
(usual care). MASS (a) dispenses all prescribed medica-
tion in the right dosage at the specified time, (b)
reminds patients to take their medications through an
alarm, sms or voicemail service and records adherence,
and (c) sends critical data about non-adherence to the
HF nurse, via a web application (CarebyWeb). The
MASS device will be provided to the patient during the
baseline visit, including an instruction how to use it and
a manual for technical support. The patients in the
intervention group will then take the monitor home and
will collect a medication roll from their own pharmacy
within one week. In a weekly notebook, patients will
report on their perceived adherence, answer some dedi-
cated questions on medication side-effects, satisfaction
with MASS, and disease-specific and generic perceived
health. After 6 months, patients will return their moni-
tor to the researcher during their usual care visit (T1).
Recordings from the MASS device to CarebyWeb will
be used as follows: (1) > 3 alerts will result into contact
by the HF nurse with the patient outside regular
appointments to identify reasons for not taking the
medication as prescribed; and (2) if any inconsistency in
medication taking behavior is being observed, the HF-
nurse will use this information at the patient’s next reg-
ular visit at the HF outpatient clinic to discuss reasons
for non-adherence and ways to address them.
Usual care
Patients randomized to the usual care arm will receive
the care as it is normally offered consisting of three vis-
its (0, 3, and 6 months after inclusion) to the HF outpa-
tient clinic of the TweeSteden hospital for a
consultation with the HF nurse. During this half hour
visit, anamnesis will be taken, a physical examination
will take place, and topics like medication adherence,
and anything the patient additionally wants to discuss
will be addressed. Patients will be treated for their HF
in accordance with the current Dutch guideline for
treatment of patients with chronic HF [4].
Statistical analysis
This trial is designed to show whether the MASS device
is effective in improving medication adherence in a
chronic HF population compared to usual care only.
Descriptive statistics (frequencies, means (±SD) will be
calculated stratified by experimental group (intervention
vs. usual care). T-tests for continuous variables and Chi-
square tests for categorical variables will enable us to
compare baseline values for both groups to formally test
the successfulness of the randomization procedure. We
will examine the effectiveness of the intervention by
using the intention-to-treat principle, with the inclusion
of all randomized participants in the statistical analyses
regardless of whether they completed the intervention
or the follow-up measurements. Missing data will be
imputed using regression imputation techniques. The
equality of subjective and objective adherence will be
assessed by means of Intraclass correlation and Cohen’s
measure for agreement, the Kappa statistic, depending
on the measure of adherence. Repeated measures analy-
sis of covariance will be used to assess differences
between the intervention and control group with respect
to changes in adherence over the six-month intervention
period, and to assess long-term effects (up to one year
post-intervention) of the intervention on medication
adherence, while taking potential confounders into
account. To determine whether the time to hospitaliza-
tion is longer for patients using the MASS device com-
pared with patients in the control group, the log-rank
test for comparison of Kaplan-Meier curves will be
used. In addition, Cox proportional hazards regression
modeling will be used to determine whether the usage
of the MASS device predicts time to the first event (i.e.
hospitalization due to HF or cardiac-related death).
Multivariate regression analyses will be used to assess
which psychological, clinical, demographic, and/or medi-
cation-related determinants predict adherence (with the
percentage of adherence as dependent variable) in
chronic HF patients and moderate the effects of the
MASS device on patient adherence. The influence of
potential effect modifiers will be examined by means of
interaction terms.
Statistical power analysis
The most demanding analysis in this trial with regard to
statistical power and sample size is the survival analysis
in which adherence is a predictor of the number of HF-
related hospitalizations. A power analysis in PASS for a
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formed, using information from the TweeSteden hospi-
tal and previous studies. Assuming an event rate of 29%
(data 2008 and 2009, TweeSteden hospital), an esti-
mated hazard ratio of between .70 and .80 [6], taking
into account an SD of 1 for our main predictor adher-
ence, and a correlation with covariating factors of on
average .30, a two-sided type I error of .05, and a mini-
mal power of 80% to detect a HR of .70, the sample size
needed for this study to be sufficiently powered is 400.
In an earlier study conducted at the same outpatient
clinic and within the same patient population, a
response rate of 78.3% was shown with a 19.9% attrition
rate [22]. Thus, in order to achieve the calculated sam-
ple size of 400 patients, we intend to include 480
patients at baseline (1:1). Based on a more conservative
response rate of 70%, 685 patients need to be
approached. With 400 patients visiting the outpatient
clinic each year (approximately 3-5 new patients/week)
inclusion of such a number within two years is feasible.
This sample size is also sufficient to test the other, less
power demanding, research questions.
Subgroup analysis
We will perform subgroup analyses for the following
subgroups: age (age ≤ 70 vs. > 70 years); gender (male
vs. female); disease severity (NYHA class II vs. class III);
dose frequency per day (1 dose vs. ≥2 doses); and cogni-
tive function (MMSE score: highest tertile vs. all others).
Discussion
The TELEMED-HF study is designed to test the efficacy
and cost-efficiency of an innovative telemonitoring solu-
tion, the MASS device, in improving medication adher-
ence as compared to usual care alone in a large group of
HF patients. Currently, a few major clinical trials have
used strategies consisting of daily telemonitoring of symp-
toms and health behaviors in HF patients [13,14]. How-
ever, the TELEMED-HF study is the first trial that
primarily focuses on improving medication adherence by
recording adherence, dispensing all prescribed medication
in the right dosage at the specified times, reminding
patients to take their medicines, and collecting informa-
tion about non-adherence from the MASS device and
responding to it. While we have chosen for a commercially
available telemonitoring device, the study is designed to
test its concept rather than the product itself, resembling
the Tele-HF study that investigated a commercially avail-
able system on health behaviors in HF patients [23].
As the MASS device is expected to train adherent
behavior, it can be considered as a behavior-based inter-
vention. To date, most studies did not examine the
effect of telemonitoring on longer term outcomes past 6
months, nor the clinical course of HF [12]. This RCT is
therefore designed to determine the effect of medication
adherence on the clinical state, disease progression,
health care consumption, and QoL with a follow-up per-
iod of one year. We will further examine the correspon-
dence between objectively and subjectively assessed
medication adherence. Finally, our aim is to identify psy-
chosocial and clinical determinants of medication adher-
ence, and their role in modulating adherence and the
effect of the telemonitoring device.
This intervention is innovative in comparison with
other telemedicine devices. First, it supplies all pills put
together in one or two small bags using pharmacy-pre-
pared medication rolls at pharmacy-specified but
patient-tailored times. Consequently, patients, partners,
or informal carers do not have to prepare their medi-
cines or a medication box weekly, reducing the chance
of making possible errors. This makes the intervention
especially suitable for the chronic HF population with
mostly elderly patients who are often care dependent,
receiving multiple different types of medication. Second,
the treating physician or HF-nurse can use the informa-
tion on pill taking behavior collected by the monitor to
discuss reasons for non-adherence during the regular
visits and if necessary, ways to address them.
The main clinical relevance of the TELEMED-HF-
study is that improved adherence may lead to a better
clinical condition of a chronic HF patient. This may
reduce the chance for hospitalization due to heart failure
deterioration, while ultimately improving the prognosis
and QoL of the patient. Furthermore, we may be able to
draw extensive conclusions on the effectiveness of the
telemonitoring device as we will include sociodemo-
graphic, clinical, and psychological variables. Self-man-
agement programs can be tailored to patients’ individual
needs by delineating distinct profiles of patients who ben-
efit from this intervention and those who may not. In the
end, the results of the effectiveness of the monitor may
be relevant for other research fields regarding chronic
patients and/or (mildly) cognitively impaired patients fol-
lowing a strict medication regimen (e.g. diabetes, chronic
obstructive pulmonary disease, post-stroke). Moreover,
the TELEMED-HF-study is expected to fulfill the grow-
ing general need to obtain more knowledge on medica-
tion adherence in chronically ill patients, and to develop
interventions from a multidimensional perspective.
From a socioeconomic perspective, the results of this
trial will enable us to examine the cost-effectiveness of
the intervention. Although initial costs are substantial,
due to the purchase price of the MASS device and
monthly rates, the subsequent reduction in health care
consumption and costs may compensate these costs tre-
mendously. Positive results may even lead to an imple-
mentation of the MASS device in clinical practice.
Without the need of a special mobile telephone
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easily provided to HF patients that are expected to ben-
efit from this type of intervention as part of the clinical
care of the HF outpatient clinic with a standardized
duration depending on the cost-efficiency.
In summary, the results of the TELEMED-HF study are
expected (a) to provide us a comprehensive understanding
of medication adherence in HF patients, (b) to indicate
whether the MASS device is effective and cost-efficient in
improving medication adherence and preventing hospitali-
zation in HF patients, and (c) to identify which subgroups
of HF patients may benefit most from MASS.
Trial Status
The TELEMED-HF trial was conceived and designed in
2010. At the time of the manuscript submission the
study protocol had full ethics approval from the Medical
Ethics Committee. The first participant will be rando-
mized in October, 2011.
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HF: heart failure; MASS: Medication adherence support system; QoL: Quality
of life.
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